- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05297409
An Observational Prospective Cohort Study for Long-term Management of Hyperkalemia in Patients With Chronic Kidney Disease or Heart Failure (HK registry)
Hyperkalemia Registry An Observational Prospective Cohort Study for Long-term Management of Hyperkalemia in Patients With Chronic Kidney Disease or Heart Failure
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Kagoshima, Japan, 890-0075
- Research Site
-
Kochi, Japan, 781-0082
- Research Site
-
Shizuoka, Japan, 410-2295
- Research Site
-
Tochigi, Japan, 321-0293
- Research Site
-
Toyama, Japan, 939-8511
- Research Site
-
Yamagata, Japan, 990-8533
- Research Site
-
-
Aichi
-
Kasugai, Aichi, Japan, 486-8510
- Research Site
-
Nagaoka, Aichi, Japan, 457-8511
- Research Site
-
Nagaoka, Aichi, Japan, 460-0001
- Research Site
-
-
Chiba
-
Matsudo, Chiba, Japan, 271-0077
- Research Site
-
-
Fukuoka
-
Chikushino, Fukuoka, Japan, 818-0058
- Research Site
-
Iizuka-shi, Fukuoka, Japan, 820-8505
- Research Site
-
Kitakyushu-shi, Fukuoka, Japan, 802-8555
- Research Site
-
-
Gunma
-
Takasaki, Gunma, Japan, 370-0001
- Research Site
-
Takasaki, Gunma, Japan, 370-8537
- Research Site
-
-
Hiroshima
-
Fukuyama, Hiroshima, Japan, 729-0104
- Research Site
-
Hirosima-shi,Naka-ku, Hiroshima, Japan, 730-8518
- Research Site
-
-
Ishikawa
-
Hakusan, Ishikawa, Japan, 924-8588
- Research Site
-
Kanazawa, Ishikawa, Japan, 920-8650
- Research Site
-
-
Kanagawa
-
Kawasaki-shi,Kawasaki-ku, Kanagawa, Japan, 210-0852
- Research Site
-
Kawasaki-shi,Miyamae-ku, Kanagawa, Japan, 216-8511
- Research Site
-
-
Mie
-
Kuwana, Mie, Japan, 511-0061
- Research Site
-
-
Miyagi
-
Sendai, Miyagi, Japan, 982-8502
- Research Site
-
-
Nagano
-
Azumino, Nagano, Japan, 399-8292
- Research Site
-
Ueda, Nagano, Japan, 386-8610
- Research Site
-
-
Niigata
-
Nagaoka, Niigata, Japan, 940-8653
- Research Site
-
-
Osaka
-
Osaka-shi,Kita-ku, Osaka, Japan, 530-0012
- Research Site
-
Sakai, Osaka, Japan, 593-8304
- Research Site
-
-
Tokyo
-
Bunkyo, Tokyo, Japan, 113-8431
- Research Site
-
Bunkyo, Tokyo, Japan, 113-8519
- Research Site
-
Itabashi, Tokyo, Japan, 173-0032
- Research Site
-
Itabashi, Tokyo, Japan, 173-8610
- Research Site
-
Shinjuku, Tokyo, Japan, 162-0054
- Research Site
-
Shinjuku, Tokyo, Japan, 162-8666
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients with hyperkalemia who meet the following criteria:
1) Being treated with potassium binders for hyperkalemia at the time of enrolment, and having started receiving potassium binders within 6 months before enrolment
Having been diagnosed as CKD (≥stage 3b) or HF diagnosed by investigators, and as defined below:
1) CKD is diagnosed based on the CKD guidelines issued by the Japanese Society of Nephrologyxxix as being either or both of condition 1 and 2 for ≥3 months
1-i) Clear signs of kidney impairment based on the results of urinalysis, imaging, blood test, or biopsy. Presence of proteinuria, especially more than 0.15 g/gCr (albuminuria more than 30 mg/gCr).
1-ii) GFR <45 mL/min/1.73m2
2) Patients with HFwill be enrolled if patients meet following criteria: 2-i) NYHA class II-IV, within 6 months 2-ii) Patients with a diagnosis or history of heart failure, hospitalization, and laboratory records of any of the following; NT-proBNP≥400 pg/ml or BNP≥100 pg/ml, or pathological findings such as abnormal cardiac function by UCG/CT/MRI/catheterization/nuclear medicine examination
- Provision of signed, written, and detailed informed consent
Exclusion Criteria:
- Currently on any chronic RRT (including hemodialysis or peritoneal dialysis >30 days, or kidney transplant) within 6 months before enrolment
- Patients with acute kidney injury (AKI)* within 6 months before enrolment
- Patients with acute heart failure within 3 months before enrolment
- Patients who received blood transfusion within 6 months before enrolment
- Patients with active malignancy or whose life expectancy is less than 6 months
- GI disturbance, chronic diarrhoea, or GI stoma if, as judged by the investigators, that condition or its treatment has an important impact on S-K values
- Autoimmune disease if, as judged by the investigators, that condition or its treatment has an important impact on S-K values
- Patients who are suspected, on the basis of laboratory data, to have pseudohyperkalemia (abnormality in the sample, a history of severe leukocytopenia or thrombocytopenia)
- Patients with recent traumatic injury
- Patients who are pregnant, lactating, or planning to become pregnant
- Current participation in a clinical trials, i.e. an interventional studies
- Presence of a condition that, in the opinion of the investigator, i) would places the subject at undue risk, or ii) would potentially jeopardizes the quality of the data to be generated, or iii) would prevent the patient from performing protocol-defined tasks for physical or mental reasons, or iv) would prevent the patient from understanding the contents of the self-administered questionnaire and responding to its questions on his/her own, or v) would, for some other reason, make the patient inappropriate for this study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Hyperkalemia patient with Chronic kidney disease
|
hyperkalemia patient with heart failure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patient characteristics including socio-demographic variables, severity of disease and comorbidities
Time Frame: 6 month
|
6 month
|
Health-Related Quality of Life
Time Frame: 6 month
|
6 month
|
Serum Potassium
Time Frame: 6 month
|
6 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Nutritional status
Time Frame: 6 month
|
6 month
|
Status of metabolic acidosis
Time Frame: 6 month
|
6 month
|
Use of healthcare resource
Time Frame: 6 month
|
6 month
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Onset or worsening of HF, any rapid decline in kidney function, GI symptoms and peripheral edema
Time Frame: 6 month
|
6 month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Urologic Diseases
- Disease Attributes
- Renal Insufficiency
- Water-Electrolyte Imbalance
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Heart Failure
- Kidney Diseases
- Renal Insufficiency, Chronic
- Hyperkalemia
Other Study ID Numbers
- D9480R00027
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperkalemia
-
Centre Integre Universitaire de Sante et Services...Canadian Institutes of Health Research (CIHR)Not yet recruitingHyperkalemia, Diminished Renal ExcretionCanada
-
AstraZenecaCompletedHyperkalemia Elevated Plasma K+ Cardiovascular Disease (CVD)Russian Federation
-
University of California, IrvineRecruitingAcute Hyperkalemia | Oral Potassium BindersUnited States
-
Vifor Pharma, Inc.RecruitingHyperkalemiaUnited States, Israel
-
University of AleppoRecruitingHyperkalemiaSyrian Arab Republic
-
Portsmouth Hospitals NHS TrustVifor PharmaRecruitingHyperkalemiaUnited Kingdom
-
Waterstone Pharmaceutical (Wuhan) Co., LTD.Completed
-
AstraZenecaCompletedHyperkalemiaUnited States, Russian Federation, Italy, Denmark
-
ZS Pharma, Inc.CompletedHyperkalemiaUnited States, Australia
-
The University of Texas Health Science Center,...Memorial Hermann HospitalCompleted